Physician profile
Raminder Singh Cheema
NPI 1588854038
$7,549.72
in general payments reported to CMS, 2019-2025
15 companies · $5,960 in 2025
The $5,960 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $1,145 · 2024: $320 · 2025: $5,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Travel and Lodging: $2,605 · Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Travel and Lodging | $2,604.91 |
| Food and Beverage | $820.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,520.10 | 2025 | |
| Olympus Corporation of The Americas | $1,235.05 | 2023-2024 | Single Use Suction Valve (Sterile), Olympus |
| United Therapeutics Corporation | $151.14 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $112.56 | 2022-2025 | Airsupra, Tezspire, Fasenra |
| Pulmonx Corporation | $103.68 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Amgen INC. | $79.30 | 2022-2023 | |
| Verona Pharma, INC. | $78.91 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.94 | 2024-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $47.49 | 2025 | Trelegy Ellipta |
| Mylan Specialty L.P. | $38.26 | 2022-2023 | Yupelri |
| Philips North America LLC | $26.47 | 2025 | Vest Therapy Und |
| Electromed, INC. | $25.32 | 2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $24.54 | 2024 | Acthar |
| Ani Pharmaceuticals, INC. | $24.43 | 2025 | Purified Cortrophin Gel |
| Edwards Lifesciences Corporation | $18.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raminder Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.